| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | EVP, Chief of Clinical Affairs | Common Stock | 444 | $1,674 | $3.77 | 15 Dec 2021 | Direct |
| Prelude Therapeutics Inc | EVP, Chief of Clinical Affairs | Employee Stock Option (right to buy) | 90,000 | 15 Feb 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 15 Feb 2022 | 1 | $0 | 4 | EVP, Chief of Clinical Affairs | 17 Feb 2022, 18:08 |
| PRLD | Prelude Therapeutics Inc | 15 Dec 2021 | 6 | -$37,368 | 4 | EVP, Chief of Clinical Affairs | 17 Dec 2021, 16:20 |
| PRLD | Prelude Therapeutics Inc | 16 Nov 2021 | 4 | -$87,081 | 4 | EVP, Chief of Clinical Affairs | 18 Nov 2021, 17:42 |
| PRLD | Prelude Therapeutics Inc | 20 Jul 2021 | 1 | $0 | 4 | EVP, Chief of Clinical Affairs | 22 Jul 2021, 18:14 |